Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity

Journal of Virology

Volumn 79, Issue 12, 2005, Pages 7478-7491

  Shayakhmetov, Dmitry M ^a   Gaggar, Anuj ^a   Ni, Shaoheng ^a   Li, Zong Yi ^a   Lieber, André ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AMINOTRANSFERASE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 9; COMPLEMENT COMPONENT C4 BINDING PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PROTEOHEPARAN SULFATE;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; EMBRYO; GENE DELIVERY SYSTEM; GENE THERAPY; HEPATITIS; HUMAN; HUMAN CELL; INFLAMMATION; INTRAVENOUS ADMINISTRATION; KUPFFER CELL; LIVER CELL; LIVER TOXICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LIPID INTERACTION; PROTEIN PROTEIN INTERACTION; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS MUTATION; VIRUS PARTICLE;

ADENOVIRUSES, HUMAN; ANIMALS; BLOOD COAGULATION FACTORS; CAPSID PROTEINS; CELL LINE; CRICETINAE; FACTOR IX; GENETIC VECTORS; HEPATOCYTES; HISTOCOMPATIBILITY ANTIGENS; HUMANS; KUPFFER CELLS; MICE; MICE, INBRED C57BL; TRANSDUCTION, GENETIC;

ADENOVIRIDAE;

EID: 18944396179     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.12.7478-7491.2005     Document Type: Article

References (60)

1. Agnello, V., G. Abel, M. Elfahal, G. B. Knight, and Q. X. Zhang. 1999. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 96:12766-12771.
2. Alemany, R., and D. T. Curiel. 2001. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther. 8:1347-1353.
3. Ben-Gary, H., R. L. McKinney, T. Rosengart, M. L. Lesser, and R. G. Crystal. 2002. Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. Mol. Ther. 6: 287-297.
4. Bernt, K. M., D. S. Steinwaerder, S. Ni, Z. Y. Li, S. R. Roffler, and A. Lieber. 2002. Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res. 62:6089-6098.
5. Branchereau, S., D. Calise, and N. Ferry. 1994. Factors influencing retroviral-mediated gene transfer into hepatocytes in vivo. Hum. Gene Ther. 5: 803-808.
6. Brown, M. S., and J. L. Goldstein. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science 232:34-47.
7. Brunetti-Pierri, N., D. J. Palmer, A. L. Beaudet, K. D. Carey, M. Finegold, and P. Ng. 2004. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into non-human primates. Hum. Gene Ther. 15:35-46.
8. Carlson, C. A., D. S. Steinwaerder, H. Stecher, D. M. Shayakhmetov, and A. Lieber. 2002. Rearrangements in adenoviral genomes mediated by inverted repeats. Methods Enzymol. 346:277-292.
9. Chroboczek, J., and B. Jacrot. 1987. The sequence of adenovirus fiber: similarities and differences between serotypes 2 and 5. Virology 161:549-554.
10. Connelly, S. 1999. Adenoviral vectors for liver-directed gene therapy. Curr. Opin. Mol. Ther. 1:565-572.
11. Crystal, R. G., B. G. Harvey, J. P. Wisnivesky, K. A. O'Donoghue, K. W. Chu, J. Maroni, J. C. Muscat, A. L. Pippo, C. E. Wright, R. J. Kaner, P. L. Leopold, P. D. Kessler, H. S. Rasmussen, T. K. Rosengart, and C. Hollmann. 2002. Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum. Gene Ther. 13:65-100.
12. Douglas, J. T., C. R. Miller, M. Kim, I. Dmitriev, G. Mikheeva, V. Krasnykh, and D. T. Curiel. 1999. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat. Biotechnol. 17:470-475.
13. Einfeld, D. A., R. Schroeder, P. W. Roelvink, A. Lizonova, C. R. King, I. Kovesdi, and T. J. Wickham. 2001. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J. Virol. 75:11284-11291.
14. Fechner, H., A. Haack, H. Wang, X. Wang, K. Eizema, M. Pauschinger, R. Schoemaker, R. Veghel, A. Houtsmuller, H. P. Schultheiss, J. Lamers, and W. Poller. 1999. Expression of coxsackie adenovirus receptor and αv-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther. 6:1520-1535.
15. Gaggar, A., Z.-Y. Li, V. Ternovoi, D. M. Shayakhmetov, N. Kiviat, and A. Lieber. 2002. Using adenoviral fiber knob domains to determine tumor susceptibility to viral cancer therapy. Mol. Ther. 5:S206.
16. Gaggar, A., D. Shayakhmetov, and A. Lieber. 2003. CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9:1408-1412.
17. Graham, F. L., and A. J. van der Eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456-467.
18. Hardonk, M. J., F. W. Dijkhuis, C. E. Hulstaert, and J. Koudstaal. 1992. Heterogeneity of rat liver and spleen macrophages in gadolinium chloride-induced elimination and repopulation. J. Leukoc. Biol. 52:296-302.
19. Herz, J., D. E. Clouthier, and R. E. Hammer. 1992. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell 71:411-421.
20. Herz, J., and D. K. Strickland. 2001. LRP: a multifunctional scavenger and signaling receptor. J. Clin. Investig. 108:779-784.
21. Hilgard, P., and R. Stockert. 2000. Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes. Hepatology 32:1069-1077.
22. Ishibashi, S., J. Herz, N. Maeda, J. L. Goldstein, and M. S. Brown. 1994. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc. Natl. Acad. Sci. USA 91:4431-4435.
23. Ji, Z. S., W. J. Brecht, R. D. Miranda, M. M. Hussain, T. L. Innerarity, and R. W. Mahley. 1993. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J. Biol. Chem. 268:10160-10167.
24. Ji, Z. S., and R. W. Mahley. 1994. Lactoferrin binding to heparan sulfate proteoglycans and the LDL receptor-related protein. Further evidence supporting the importance of direct binding of remnant lipoproteins to HSPG. Arterioscler. Thromb. 14:2025-2031.
25. Kochanek, S., G. Schiedner, and C. Volpers. 2001. High-capacity 'gutless' adenoviral vectors. Curr. Opin. Mol. Ther. 3:454-463.
26. Leissner, P., V. Legrand, Y. Schlesinger, D. A. Hadji, M. van Raaij, S. Cusack, A. Pavirani, and M. Mehtali. 2001. Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Ther. 8:49-57.
27. Lieber, A., C. Y. He, L. Meuse, C. Himeda, C. Wilson, and M. A. Kay. 1998. Inhibition of NF-κB activation in combination with Bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver. J. Virol. 72:9267-9277.
28. Lieber, A., C. Y. He, L. Meuse, D. Schowalter, I. Kirillova, B. Winther, and M. A. Kay. 1997. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 71:8798-8807.
29. Lieber, A., M. J. Vrancken Peeters, and M. A. Kay. 1995. Adenovirus-mediated transfer of the amphotropic retrovirus receptor cDNA increases retroviral transduction in cultured cells. Hum. Gene Ther. 6:5-11.
30. Lin, H. F., N. Maeda, O. Smithies, D. L. Straight, and D. W. Stafford. 1997. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 90:3962-3966.
31. Liu, Q., and D. A. Muruve. 2003. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther. 10:935-940.
32. Lozier, J. N., G. Csako, T. H. Mondoro, D. M. Krizek, M. E. Metzger, R. Costello, J. G. Vostal, M. E. Rick, R. E. Donahue, and R. A. Morgan. 2002. Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum. Gene Ther. 13:113-124.
33. Lundstrom, K. 2003. Latest development in viral vectors for gene therapy. Trends Biotechnol. 21:117-122.
34. Martin, K., A. Brie, P. Saulnier, M. Perricaudet, P. Yeh, and E. Vigne. 2003. Simultaneous CAR- and αv integrin-binding ablation fails to reduce Ad5 liver tropism. Mol. Ther. 8:485-494.
35. Mickelson, C. A. 2000. Department of Health and Human Services National Institutes of Health Recombinant DNA Advisory Committee. Minutes of meeting March 8-10, 2000. Hum. Gene Ther. 11:2159-2192.
36. Morral, N., W. K. O'Neal, K. Rice, M. M. Leland, P. A. Piedra, E. Aguilar-Cordova, K. D. Carey, A. L. Beaudet, and C. Langston. 2002. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum. Gene Ther. 13:143-154.
37. Muruve, D. A., M. J. Barnes, I. E. Stillman, and T. A. Libermann. 1999. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 10: 965-976.
38. Neels, J. G., B. M. van Den Berg, K. Mertens, H. ter Maat, H. Pannekoek, A. J. van Zonneveld, and P. J. Lenting. 2000. Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein. Blood 96:3459-3465.
39. Nunes, F. A., E. E. Furth, J. M. Wilson, and S. E. Raper. 1999. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum. Gene Ther. 10:2515-2526.
40. Raper, S. E., M. Yudkoff, N. Chirmule, G. P. Gao, F. Nunes, Z. J. Haskal, E. E. Furth, K. J. Propert, M. B. Robinson, S. Magosin, H. Simoes, L. Speicher, J. Hughes, J. Tazelaar, N. A. Wivel, J. M. Wilson, and M. L. Balshaw. 2002. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum. Gene Ther. 13:163-175.
41. Reid, T., E. Galanis, J. Abbruzzese, D. Sze, J. Andrews, L. Romel, M. Hatfield, J. Rubin, and D. Kirn. 2001. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther. 8:1618-1626.
42. Roelvink, P. W., A. Lizonova, J. G. Lee, Y. Li, J. M. Bergelson, R. W. Finberg, D. E. Brough, I. Kovesdi, and T. J. Wickham. 1998. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol. 72:7909-7915.
43. Schnell, M. A., Y. Zhang, J. Tazelaar, G. P. Gao, Q. C. Yu, R. Qian, S. J. Chen, A. N. Varnavski, C. LeClair, S. E. Raper, and J. M. Wilson. 2001. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol. Ther. 3:708-722.
44. Seglen, P. O. 1979. Hepatocyte suspensions and cultures as tools in experimental carcinogenesis. J. Toxicol. Environ. Health 5:551-560.
45. Shayakhmetov, D. M., Z.-Y. Li, S. Ni, and A. Lieber. 2004. Analysis of adenovirus liver sequestration, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J. Virol. 78:5368-5381.
46. Shayakhmetov, D. M., Z. Y. Li, S. Ni, and A. Lieber. 2002. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res. 62:1063-1068.
47. Shayakhmetov, D. M., Z. Y. Li, V. Ternovoi, A. Gaggar, H. Gharwan, and A. Lieber. 2003. The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. J. Virol. 77:3712-3723.
48. Shayakhmetov, D. M., and A. Lieber. 2000. Dependence of adenovirus infectivity on length of the fiber shaft domain. J. Virol. 74:10274-10286.
49. + cells by a retargeted adenovirus vector. J. Virol. 74:2567-2583.
50. Shenk, T. 1996. Adenoviridea, p. 2111-2148. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
51. Smith, T., N. Idamakanti, H. Kylefjord, M. Rollence, L. King, M. Kaloss, M. Kaleko, and S. C. Stevenson. 2002. In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol. Ther. 5:770-779.
52. Smith, T. A., N. Idamakanti, J. Marshall-Neff, M. L. Rollence, P. Wright, M. Kaloss, L. King, C. Mech, L. Dinges, W. O. Iverson, A. D. Sherer, J. E. Markovits, R. M. Lyons, M. Kaleko, and S. C. Stevenson. 2003. Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum. Gene Ther. 14:1595-1604.
53. Smith, T. A., N. Idamakanti, M. L. Rollence, J. Marshall-Neff, J. Kim, K. Mulgrew, G. R. Nemerow, M. Kaleko, and S. C. Stevenson. 2003. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum. Gene Ther. 14:777-787.
54. Takami, M., I. Kasuya, and H. Tsunoo. 1992. Polymerized albumin receptor on rat liver cells. J. Biochem. (Tokyo) 111:714-721.
55. Thomas, C. E., A. Ehrhardt, and M. A. Kay. 2003. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4:346-358.
56. Vrancken Peeters, M. J., A. L. Perkins, and M. A. Kay. 1996. Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer. BioTechniques 20:278-285.
57. Windler, E., J. Greeve, B. Levkau, V. Kolb-Bachofen, W. Daerr, and H. Greten. 1991. The human asialoglycoprotein receptor is a possible binding site for low-density lipoproteins and chylomicron remnants. Biochem. J. 276: 79-87.
58. Worgall, S., G. Wolff, E. Falck-Pedersen, and R. G. Crystal. 1997. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8:37-44.
59. Xia, D., L. J. Henry, R. D. Gerard, and J. Deisenhofer. 1994. Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution. Structure 2:1259-1270.
60. Yu, K. C., W. Chen, and A. D. Cooper. 2001. LDL receptor-related protein mediates cell-surface clustering and hepatic sequestration of chylomicron remnants in LDLR-deficient mice. J. Clin. Investig. 107:1387-1394.